Phase II Clinical Trial Results for iniparib's Treatment of Glioblastoma

Glioblastoma patients are more or less resistant to existing treatment optionsAs a newly developed drug, Iniparib has a unique mechanism of action, combining radiotherapy and tamoxifen with 17.2 mg/kg per week, demonstrating good anti-tumor activity and tolerance, which deservefurther further study and application- From the article(Ref: Blakeley JO, et alClin Cancer Res2019 Jan 1;2019)1:73-79doi: 10.1158/1078-0432.CCR-18-0110Epub 2018 Aug 21Jaishri Oof Johns Hopkins University's Department of Neurology, Neurosurgery and OncologyBlakeley et alconducted a Phase II clinical trial evaluating Iniparib, a 4-iodo-3 nitrobenzamide (4-iodo-3-nitrobenzamide) combined with radiotherapy and tamoxamine to treat newly diagnosed glioblastoma (GBM) adult patients, with the results compared to the results of the EORTC/NCIC III clinical trialThe article was published online by Clinical Cancer Research in August 2018study included 83 GBM patients, age 27-81 years, median age 58 years, 83 patients participated in the safety analysis, of which 81 analyzed the efficacyOf the 81 patients, 5 were tested for safety tests to assess Iniparib's maximum tolerable dose and toxicity tests, while the remaining 76 were treated with iniparib combined with radiotherapy and tamoxifen treatment (Figure 1)The main result of the experiment is the overall median lifetime (mOS), with secondary results being the incidence of adverse eventsFigure 1 Drug safety analysis and clinical efficacy research trials in 81 patients with GBM results showed that in patients treated with iniparib, the overall median survival was extended to 22 months (95% CI, 17-24 months); The most common level 3 or 4 adverse events included 15 cases (18%) decreased platelet count, 8 cases (10%) decreased neutrophil count, 4 (5%) tiredness and 3 cases (4%) of rashes Nine patients were discontinued due to adverse events authors argue that glioblastoma patients are more or less resistant to existing treatment options As a newly developed drug, Iniparib has a unique mechanism of action, combining radiotherapy and tamoxifen with 17.2 mg/kg per week, demonstrating good anti-tumor activity and tolerance, which deservefurther further study and application.